



InDevR

Enabling Vaccines

VaxArray® Coronavirus SeroAssay

Bringing vaccine analytics
Into the 21st century

VaxArray CoV SeroAssay

Multiplexed Coronavirus Serological Testing

By printing an array of antigen targets, the VaxArray Coronavirus SeroAssay can analyze antibody response against multiple coronaviruses. Conduct vaccine efficacy testing against endemic and pandemic coronavirus spike proteins in only 2 hours from less than 10 µL of sample.

Subtype	Captures	Source	Protein Domain
SARS-nCoV-2	3	Mammalian, Insect	Full Spike, RBD, and ECD
SARS-nCoV-1	1	Mammalian	RBD
MERS	1	Mammalian	RBD
HKU1	1	Mammalian	RBD
OC43	1	Insect	Full Spike
229E	1	Mammalian	RBD
NL63	1	Mammalian	RBD

Standardized

Ready to order assay kits built under ISO:13485 allow standardization across laboratories.

Quantitative Results

Don't rely on yes/no results for vaccine development. Quantitative data enables detailed comparisons of your vaccine candidates.

Enhanced Sensitivity

VaxArray SeroAssays are more sensitive than most standard ELISAs. Larger linear ranges and lower limits of detection allow for assay flexibility.

Endemic Coronaviruses

Test reactivity to circulating endemic coronavirus strains at the same time as testing serological response to the novel SARS-CoV-2 strain. Understand patient immunity profiles prior to clinical testing.

VaxArray Coronavirus SeroAssay

Designed for the VaxArray Platform


- 2 hours from samples to result
- 30 minutes hands on time
- Up to 64 samples per run
- Multiplexed analysis
- Up to 576 datapoints generated



Performance

Metric Specifications

Limit of Quantification	≤ 1 ng/mL
Minimum Sample Volume	≤ 10 µL
Clinical Specificity	100%
Clinical Sensitivity	98%
Linear Range (ULOQ/LLOQ)	100x
Sample Compatibility	Mouse or Human Serum



Example Results

The following data outlines serological response to multiple coronavirus strains. Quantitative data allows for an in depth understanding of serological response, enabling both vaccine clinical studies and serological prevalence testing.

	Pandemic Coronaviruses					Endemic Coronaviruses			
	nCoV (S1+S2)	nCoV (S1)	nCoV (S2)	SARS (S1)	MERS (S1)	HKU1 (S1)	OC43 (S1 + S2)	229E (S1)	NL63 (S1)
Negative SARS-CoV-2 PCR Test									
Positive SARS-CoV-2 PCR Test									

VaxArray Coronavirus SeroArray results from 10 samples of human serum. The top five samples in the table above were negative for SARS-CoV-2 while the bottom five were positive for SARS-CoV-2, and both positives and negatives were confirmed by RT-PCR test. Darker coloring is indicative of a stronger signal on the VaxArray Coronavirus SeroAssay. These data are representative samples from a larger study involving 117 samples of human serum.

Multi-antigen Confirmation

By analyzing response to multiple antigens simultaneously, the VaxArray Coronavirus SeroAssay confirms serological response using multidimensional analysis. Don't rely on response to only one antigen. VaxArray's Clinical sensitivity of 98% sets a new standard for coronavirus serological testing.



Testing Services

Our analytical experts are ready to provide quantitative analysis of your serum samples. Rapid turnaround times and multiplex analysis speed research and development. Or setup the VaxArray Platform in your lab and gain access to a portfolio of VaxArray compatible assays.



Learn more

2100 Central Ave Suite 106, Boulder, CO 80301

indevr.com | 303.402.9100 | sales@indevr.com

InDevR is a life science tools company developing analytical technologies for vaccine research. Enabling the safe, rapid and effective production of vaccines is our mission.